Nucleic acids encoding complement component C5 antibodies

Patent metadata

Field	Value
Publication number	US-9932395-B2
Application number	US-201715645022-A
Country	US
Kind code	B2
Filing date	Jul 10, 2017
Priority date	Feb 20, 2014
Publication date	Apr 3, 2018
Grant date	Apr 3, 2018

Abstract

The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.

First claim

We claim:

1. A nucleic acid molecule encoding an anti-C5 antibody, wherein the antibody binds to C5 and inhibits complement dependent hemolysis, but does not block C5a formation, wherein the antibody comprises a first amino acid sequence and a second amino acid sequence, further wherein:
(a) the first sequence comprising:
(i) a CDR1 selected from the group consisting of SEQ ID NOs:13, 19, 25, 31, 37 and 43;
(ii) a CDR2 selected from the group consisting of amino acids sequence GTS (SEQ ID NOS: 14 and 20), SGS (SEQ ID NO: 26), RTS (SEQ ID NO: 32), YTS (SEQ ID NO: 38), and WAS (SEQ ID NO: 44); and
(iii) a CDR3 selected from the group consisting of SEQ ID NOs:15, 21, 27, 33, 39 and 45; and

(b) the second sequence comprising:
(i) a CDR1 selected from the group consisting of SEQ ID NOs:16, 22, 28, 34, 40 and 46;
(ii) a CDR2 selected from the group consisting of SEQ ID NOs:17, 23, 29, 35, 41 and 47; and
(iii) a CDR3 selected from the group consisting of SEQ ID NOs:18, 24, 30, 36, 42 and 48.

2. The nucleic acid molecule according to claim 1 , wherein the nucleic acid molecule is operably linked to a control sequence.

Assignees

• Allergan Inc
• Xencor Inc

Inventors

• Baciu Peter C
• Liang Yanbin
• Guu Jason
• Bernett Matthew
• Muchhal Umesh
• Desjarlais John

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C07K16/18 Primary

  against material from animals or humans · CPC title